The effect of Glucomannan on fasting and postprandial blood glucose in adults: a systematic review and meta-analysis of randomized controlled trials

What this study found

Overall, glucomannan reduced fasting blood glucose but did not significantly improve postprandial glucose. Across 6 trials, fasting blood glucose decreased by WMD -0.60 mmol/L (95% CI -1.16 to -0.05; P=0.03), with a larger reduction in participants with type 2 diabetes (WMD -1.28 mmol/L, 95% CI -2.54 to -0.02; P=0.04). Postprandial glucose evidence was limited and inconsistent across 2 studies (n=42), with one report showing a reduction (WMD -3.60 mmol/L, 95% CI -5.20 to -2.00) and another showing no significant effect (WMD -0.52 mmol/L, 95% CI -5.09 to 0.95). The authors concluded that…

Study & population

This systematic review and meta-analysis included 6 randomized controlled trials with 124 adults aged 18 years or older.

Intervention

Glucomannan supplementation was evaluated at doses ranging from 3 to 15 g/day for 4 to 12 weeks across six randomized trials, compared with control conditions.

Key limitation

The evidence base was small, with only 6 trials and short follow-up periods of 4 to 12 weeks.

View full study detailsView sourceOpen PDF